BPDCN – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

BPDCN is a rare indication with a low diagnosis rate varying with geographies and ancestry. The estimated incidence in the USA and EU5 has been reported ~1300 cases and ~745 cases respectively. The incidence of diagnosed cases is low in Japan however China stands with an equal number of incidence diagnosed as the USA.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Blastic-plasmacytoid-dendritic-cell-neoplasm-BPDCN-forecast

Comprehensive insight on patient segmentation based on Pheno-typic (Immature, Intermediate, & Mature), Stages (I, II, III and IV), Grade (I, II, III, IV, and v), identified biomarker split (CD4, CD56, CD123, and TCL-1, etc.), Clinical Manifestations has been provided into the epidemiology (Incidence and Prevalence) section of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and its treatment in the 8 MM countries, covering the USA, Germany, France, Italy, Spain, UK, Japan, and China

CI IMAGE

Apart from the approved tagraxofusperzs which is from Stemline, there are several companies trying to bring products to the market. The leading pipeline product is UCART123 from Cellectis S.A, SL-401 from Stemline Therapeutics, XmAb14045 from Xencor, Inc. IMGN632 from ImmunoGen, Inc. are under different stages of development. A phase 1 study with CD123-directed CAR T-cells is underway in patients with AML and BPDCN. In addition to the CD123-binding domain, this CAR construct includes a truncated epidermal growth factor receptor (EGFRt). A phase 1 study to determine the safety and tolerability of XmAb14045 is currently underway in patients with CD123- express-ing hematologic malignancies, including AML, B-cell ALL, BPDCN, and chronic myeloid leukemia (CML). IMGN632 is an antibody-drug conjugate that consists of a humanized anti-CD123 antibody fused to an indolino-benzodiazepine agent (IGN). When delivered to a target cell via the anti-CD123 antibody, the IGN payload alkylates DNA without crosslinking, which kills the CD123-expressing target cell

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
childhood-onset Idiopathic Nephrotic Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Chronic Myeloid Leukemia (CML) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Hypoplastic Left Heart Syndrome (HLHS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Hepatoblastoma (HB) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Hyperkalemia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: BPDCN market forecast, Blastic plasmacytoid dendritic cell neoplasm, BPDCN, BPDCN market outlook report, BPDCN competitive landscape